DENVER, CO—Longer-term follow-up data from the ABSORB II and III trials confirm the significantly increased risk of thrombotic events with the Absorb bioresorbable vascular scaffold (BVS; Abbott ...

Physicians in the United States will now have access to the first commercially available “dissolving” stent for the treatment of patients with coronary artery disease following today’s US Food and ...

Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...

Absorb, Abbott's coronary stent system made to fully dissolve in the patient's body, has finally been approved by FDA. The agency's nod comes as the device is already available in more than 100 ...